Search Results - "Dieudonne, Yannick"

Refine Results
  1. 1
  2. 2

    B cells in primary antiphospholipid syndrome: Review and remaining challenges by Dieudonné, Yannick, Guffroy, Aurélien, Poindron, Vincent, Sprauel, Pauline Soulas, Martin, Thierry, Korganow, Anne-Sophie, Gies, Vincent

    Published in Autoimmunity reviews (01-05-2021)
    “…It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Primary immunodeficiencies and lymphoma: a systematic review of literature by Herber, Mathilde, Mertz, Philippe, Dieudonné, Yannick, Guffroy, Blandine, Jung, Sophie, Gies, Vincent, Korganow, Anne-Sophie, Guffroy, Aurélien

    Published in Leukemia & lymphoma (28-01-2020)
    “…The management of lymphoma in patients with primary immunodeficiency (PID) is challenging because of its poor prognosis and complex therapeutic approaches. We…”
    Get full text
    Journal Article
  5. 5

    Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN by Dieudonné, Yannick, Gies, Vincent, Guffroy, Aurélien, Keime, Céline, Bird, Anna K., Liesveld, Jane, Barnas, Jennifer L., Poindron, Vincent, Douiri, Nawal, Soulas-Sprauel, Pauline, Martin, Thierry, Meffre, Eric, Anolik, Jennifer H., Korganow, Anne-Sophie

    Published in Journal of autoimmunity (01-08-2019)
    “…Systemic lupus (SLE) is characterized by a break of B cell tolerance that plays a central role in disease pathophysiology. An early checkpoint defect occurs at…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Paraplegia as a presentation of primary hyperoxaluria by Dieudonné, Yannick, Eprinchard, Laure, Léon, Emilie, Oswald, Pierre, Gressel, Anne, Carre, Sophie, Dimitrov, Yves

    Published in CEN case reports (01-11-2018)
    “…30% of the patients suffering from hyperoxaluria type 1 are diagnosed only when they already had reached end-stage renal disease. We report the case of a…”
    Get full text
    Journal Article
  12. 12

    Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine by Gies, Vincent, Bekaddour, Nassima, Dieudonné, Yannick, Guffroy, Aurélien, Frenger, Quentin, Gros, Frédéric, Rodero, Mathieu Paul, Herbeuval, Jean-Philippe, Korganow, Anne-Sophie

    Published in Frontiers in immunology (02-07-2020)
    “…As the world is severely affected by COVID-19 pandemic, the use of chloroquine and hydroxychloroquine in prevention or for the treatment of patients is allowed…”
    Get full text
    Journal Article
  13. 13

    Immune Defect in Adults With Down Syndrome: Insights Into a Complex Issue by Dieudonné, Yannick, Uring-Lambert, Beatrice, Jeljeli, Mohamed Maxime, Gies, Vincent, Alembik, Yves, Korganow, Anne-Sophie, Guffroy, Aurélien

    Published in Frontiers in immunology (08-05-2020)
    “…Children with Down syndrome (DS) suffer from recurrent respiratory infections, which represent the leading cause of mortality during childhood. This…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Infection risk among adults with down syndrome: a two group series of 101 patients in a tertiary center by Guffroy, Aurélien, Dieudonné, Yannick, Uring-Lambert, Beatrice, Goetz, Joelle, Alembik, Yves, Korganow, Anne-Sophie

    Published in Orphanet journal of rare diseases (11-01-2019)
    “…Down syndrome (DS) is the most common form of viable chromosomal abnormality. DS is associated with recurrent infections, auto-immunity and malignancies in…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    HHV8-Positive Multicentric Castleman's Disease and Thrombotic Thrombocytopenic Purpura among HIV-Positive Patients by Pasquer, Roxane, Dieudonné, Yannick, Decours, Pauline, Hinschberger, Olivier, Nicolae, Alina, Martinot, Martin

    “…Castleman's disease (CD) and thrombotic thrombocytopenic purpura (TTP) are rare diseases that can affect the general population, especially those with HIV…”
    Get full text
    Journal Article
  20. 20